1. In non-small cell lung cancer, inv (2) (P21; P23) forms a molecular subunit of the fusion gene EML4-ALK, which is the target of the targeted drug Crizotinib.
2. A new EML4-ALK evaluation item was added to the 2010 non-small cell lung cancer Clinical guidelines for the prediction of the efficacy of ALK inhibitors.